The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus

B. A. Lemkes*, L. Bahler, P. W. Kamphuisen, A. K. Stroobants, E. J. van den Dool, J. B. Hoekstra, R. Nieuwland, V. E. Gerdes, F. Holleman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

Background: Low-dose aspirin seems to offer no benefit in the primary prevention of cardiovascular disease in type 2 diabetes mellitus (DM2). The anti-platelet effect may be diminished by poor glycemic control or inadequate dosing of aspirin. Objectives: To study the effects of both glycemic control and increasing aspirin dose on platelet response to aspirin in DM2 patients and matched controls. Patients/methods: Platelet effects of increasing doses of aspirin (30, 100 and 300 mg daily) were prospectively assessed in 94 DM2 patients and 25 matched controls by measuring thromboxane levels in urine (11-dhTxB2) and platelet aggregation using VerifyNow(R) and light transmission aggregometry (LTA). DM2 patients were stratified for glycemic control (hemoglobin-A1c [HbA1c] = 69 mmol mol(-1)). Results: At baseline, median 11-dhTxB2 excretion was higher in the poorly controlled patients (77 ng mmol(-1)), and the moderately controlled (84 ng mmol(-1)) compared with the well-controlled patients (64 ng mmol(-1)) and controls (53 ng mmol(-1)), P <0.01. Next, 30 mg of aspirin reduced 11-dhTxB2 excretion to 31, 29 and 24 ng mmol(-1) in the poorly, moderately and well-controlled patients, respectively, and to 19 ng mmol(-1) in controls, P <0.001. VerifyNow(R) and LTA were also incompletely suppressed in DM2 patients using 30 mg of aspirin, but 100 mg resulted in similar platelet suppression in all groups, with no additional effect of 300 mg. Conclusions: DM2 patients with inadequate glycemic control (HbA1c > 53 mmol mol(-1)) have higher baseline platelet activity and incomplete suppression of platelet activity with 30 mg of aspirin. However, 100 mg of aspirin leads to optimal inhibition irrespective of glycemic control, and 300 mg does not further improve platelet suppression.

Original languageEnglish
Pages (from-to)639-646
Number of pages8
JournalJOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume10
Issue number4
DOIs
Publication statusPublished - Apr-2012

Keywords

  • aspirin
  • DM2
  • glycemic control
  • platelet
  • RANDOMIZED CONTROLLED-TRIALS
  • CARDIOVASCULAR EVENTS
  • THROMBOXANE BIOSYNTHESIS
  • MYOCARDIAL-INFARCTION
  • PRIMARY PREVENTION
  • HIGH-RISK
  • RESISTANCE
  • METAANALYSIS
  • STROKE
  • COMPLICATIONS

Cite this